Mr
Douglas
Drysdale

Partner & Patent Attorney

Glasgow Office

Life sciences

Telephone. +44(0) 141 229 5800
Mobile. +44(0) 783 322 8216
Email. [email protected]

Experience

Douglas specialises in global patent strategy, filing and prosecution, advising a wide range of clients on how to build and maximise the value of their IP estate. He is also extremely experienced in patent opposition and appeals, regularly representing his clients in high profile hearings at the EPO. Douglas and his team represent leading biotech and life science companies, as well as several universities. His clients appreciate his desire to understand both their business and their technology.

Qualifications

Patent Attorney

Chartered (UK)
European


BSC

Molecular Biology - 1st Class Honours

MSC

MSc - Management of IP Law - Queen Mary's University of London

Publications

IAM Strategy 300 2021

View publication online

G1/21 hearing at the EPO

View publication online

T0694/16 - New EPO Technical Board of Appeal decision regarding personalised healthcare inventions

View publication online

Conferences: 2021

July 2nd 2021

G1/21 hearing at the EPO - July

Attended

Event details

Conferences: 2020

January 28th 2020

IAM Pharma & Biotech IP Summit 2020 - London

Speaker

Event details

Related News

Artificial intelligence inventions in healthcare – can you patent them in Europe?

Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …

Read article

Patenting digital mental health

Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder [1]. …

Read article

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article

Patentability of Simulations in Europe

Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …

Read article

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details
Event - 10th May 2022

HGF UPC events in Germany and Austria 2022

HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …

Event details
Event - 23rd March 2022

HGF webinar: Getting your first filing right

HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.